2014
DOI: 10.1016/j.cellsig.2013.11.005
|View full text |Cite
|
Sign up to set email alerts
|

Evidence for a regulatory role of Cullin-RING E3 ubiquitin ligase 7 in insulin signaling

Abstract: Dysfunctional regulation of signalling pathways downstream of the insulin receptor plays a pivotal role in the pathogenesis of insulin resistance and type 2 diabetes. In this study we report both in vitro and in vivo experimental evidence for a role of Cullin-RING E3 ubiquitin ligase 7 (CRL7) in the regulation of insulin signalling and glucose homeostasis. We show that Cul7−/− mouse embryonic fibroblasts displayed enhanced AKT and Erk MAP kinase phosphorylation upon insulin stimulation. Depletion of CUL7 by RN… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
32
0

Year Published

2014
2014
2022
2022

Publication Types

Select...
4
3
1

Relationship

1
7

Authors

Journals

citations
Cited by 32 publications
(35 citation statements)
references
References 38 publications
3
32
0
Order By: Relevance
“…4B, CUL7 depletion significantly enhanced phosphorylation of both AKT (AKT pS473 ) and Erk1/2 (Erk pT202/pY204 ). Similar results were also observed in C2C12 cells (23) (24), by quantitative real-time PCR (Fig. 4C).…”
Section: Sv40 Lt Enhances Activation Of Irs1 Downstream Signaling Patsupporting
confidence: 74%
See 1 more Smart Citation
“…4B, CUL7 depletion significantly enhanced phosphorylation of both AKT (AKT pS473 ) and Erk1/2 (Erk pT202/pY204 ). Similar results were also observed in C2C12 cells (23) (24), by quantitative real-time PCR (Fig. 4C).…”
Section: Sv40 Lt Enhances Activation Of Irs1 Downstream Signaling Patsupporting
confidence: 74%
“…5). In addition, CUL7 silencing by siRNA was shown to prevent insulin-induced degradation of IRS1 in C2C12 myotubes (23), thus further underscoring the requirement of CUL7 for the control of IRS1 homeostasis. These differences might be due to the complexity of multiple E3 ligases controlling IRS1 stability (35)(36)(37).…”
Section: Sv40 Lt-positive Carcinoma Displays Higher Irs1 Protein Levementioning
confidence: 99%
“…There is currently some uncertainty about the mechanism of mTORC2 regulation by insulin (86), because both positive and negative feedback loops involving Akt and mTORC1 3 S6K signaling have been demonstrated in different cell types (66,87). However, a growing literature connects mTORC2 to the proteasome-mediated degradation of Irs1 in cultured cells (88,89) and possibly in animal tissues (11). The mechanism described in cultured cells involves mTORC2 phosphorylation and stabilization of Fbxw8 (F-box and WD repeat domain containing 8), the substrate-targeting subunit of cullin-RING ligase CRL7 (88), but also relies upon phosphorylation of Ser-302…”
Section: Irs1mentioning
confidence: 99%
“…Numerous mechanisms regulate the strength or duration of this signaling, including variable expression or stability of the insulin receptor isoforms A and B, or of their proximal downstream components, including IRS1, IRS2, IRS3, IRS4, PI3K, and Akt (7). Diverse regulatory proteins and pathways, including GRB10 (8), phosphatidylcholine transfer protein (9), MG53/ TRIM72 (muscle-specific mitsugumin 53/tripartite motif 72) (10), the cullin RING ligase CRL7 (cullin RING E3 ubiquitin ligase 7) (11), and the Lin28/Let-7 axis (12), can each affect these proximal components to promote insulin resistance. Protein and lipid phosphatases, including PP2A, PTPN1 (tyrosineprotein phosphatase nonreceptor type 1, also known as PTP1B), and PTEN (phosphatase and tensin homolog), can also negatively regulate signaling through the insulin receptor 3 IRS 3 PI3K pathway (13)(14)(15).…”
mentioning
confidence: 99%
“…In vivo , Cul7 +/− or Fbxw8 +/− mice exhibited elevated PI3K/AKT activation in skeletal muscle tissue upon insulin stimulation. CRL7 also inhibits PI3K/AKT activities in skeletal muscle cells . Delineating these metabolic functions of CRL7 will provide data for the development of novel therapeutic strategies for the treatment of insulin resistance and type 2 diabetes.…”
Section: Directly Targeting Insulin Signalling Moleculesmentioning
confidence: 99%